Supporting people in hospitals across South Australia through vital health and medical research and improved patient care.
Meet our passionate and dedicated team.
Meet our Board and Governance team.
THRF adopts extremely high transparency standards when reporting our financials.
Supports research into the detection, management & treatment of breast cancer.
Funding research into prostate cancer prevention, detection & treatment.
Improving heart health through advances in knowledge & research to beat heart disease.
Our aim is to reduce & eliminate the high incidence of chronic kidney disease and diabetes.
Supports health and wellbeing research & programs for veterans, emergency service personnel and their families.
Driving collaboration, innovation & research to develop best-practice arts, design & health programs.
Supporting world-class stroke research to improve prevention, diagnosis & acute treatment to cure stroke.
Providing donor stool to treat patients with bowel conditions and foster research into faecal transplant as a treatment.
Do you want to join our team? Check out current career opportunities here.
View some of the commonly asked questions about our organisation.
We are so grateful to those who donate their time and skills to support life-changing medical research. Find out more…
Get in touch with us here.
World-first research is underway at the Basil Hetzel Institute for Translational Health Research (BHI) focusing on using our own immune system to fight solid cancers such as breast cancer with potential for other cancers.
Leading this revolutionary research is Professor Andreas Evdokiou who was awarded the Margaret Elcombe Research Fellowship, thanks to a generous donor from The Hospital Research Foundation (THRF) in partnership with Australian Breast Cancer Research (ABCR).
Prof Evdokiou, together with Dr Irene Zinonos, PhD student Namfon (Bee) Pantarat and Masters student Panos Panagopoulos are developing a non-invasive injectable gel filled with patient’s own cancer fighting T cells to be targeted directly to the cancerous tumour site.
“The T cells will be infused into the gel, keeping them together locked in and the gel will be injected into the tumour environment where the T cells will identify and eliminate cancer cells whilst leaving normal cells unharmed,” Prof Evdokiou said.
“This is the first time that such an approach has been developed and if successful, it will maximise the success of current surgical interventions. Potentially this could be an alternative method from chemotherapy and radiotherapy which are often the therapeutic standards after surgically removing the tumour,” Prof Evdokiou said.
With previous research already demonstrating promising results, Prof Evdokiou is hoping to identify the best injectable system with the ideal characteristics for T cells to survive and migrate to the tumour site whilst maintaining their effectiveness of killing cancer cells.
With this research being a potential therapeutic treatment for breast cancer, Prof Evdokiou is collaborating with researchers in Australia and overseas, including the Memorial Sloan Kettering Cancer Centre in New York, one of the world’s top cancer centres.
This groundbreaking research has vital potential for those cancers that are difficult or dangerous to remove such as brain cancer and spinal cancers. It will also benefit those patients who are medically inoperable due to other health conditions such as heart disease or cannot withstand surgery.
It is thanks to your support that Prof Evdokiou and his team have this opportunity to continue their fight against cancer, potentially saving the lives of the thousands of Australian women fighting breast cancer.
“We are extremely grateful to have been awarded the Margaret Elcombe Fellowship provided through THRF and ABCR and the generous Margaret Elcombe who’s made this possible. These much needed funds will ensure the successful completion of this preclinical project that will help us move quickly towards translating this into clinical practice,” Prof Evdokiou said.
We look forward to updating you on Prof Evdokiou and his teams promising research as together, with your support, they continue the fight against breast cancer.
If you like to support this revolutionary research please click here to make a donation.
Whilst estrogen receptor positive breast cancer has a targeted treatment strategy, many patients develop resistance, leaving them with no option other than chemotherapy. Now these women have hope! read more
Did you know, every day in Australia approximately 50 people are diagnosed with breast cancer? read more
It was a pain in her right breast, like that of a torn muscle, which led young mother Kate Shields to a breast cancer diagnosis that she never saw coming. In January last year the 38-year-old mother was diagnosed with aggressive hormonal breast cancer. read more
Always fit and healthy, 56-year-old Deb Holsman never thought she would be diagnosed with breast cancer, let alone one of the most heartbreaking forms of the disease. read more
The Breast Cancer Research Unit at the Basil Hetzel Institute for Translational Health Research (BHI) are determined to develop a new immunotherapy treatment to target breast cancer and other heartbreaking cancers affecting our community. read more
Thanks to your generous support, each year The Hospital Research Foundation (THRF) funds travel grants to support researchers and students to attend various conferences and meetings relevant to their field of research, having the opportunity to network with fellow researchers around the globe. read more
Head of the Cell Signalling Laboratory at the Centre for Cancer Biology (CCB), Associate Professor Yeesim Khew-Goodall is leading a crucial research project focused on overcoming resistance to cancer therapy, particularly in triple negative breast cancer. read more
Can you imagine being diagnosed with a type of cancer that has no targeted treatments? This could change thanks to researchers at the Basil Hetzel Institute for Translational Health Research (BHI) who are working hard to investigate possible treatments for triple negative breast cancer. read more
Thanks to the incredible generosity of one of our very special donors, Dr Margaret Elcombe, our researchers have been awarded the Elcombe Pre-Clinical Project Grant to pursue a promising new treatment avenue for breast cancer that has spread which if successful would be far less toxic than current treatments. read more